Cargando…

Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives

Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Shchelochkov, Oleg A., Dickinson, Klara, Scharschmidt, Bruce F., Lee, Brendan, Marino, Miguel, Le Mons, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963256/
https://www.ncbi.nlm.nih.gov/pubmed/27493880
http://dx.doi.org/10.1016/j.ymgmr.2016.07.003
_version_ 1782444933991366656
author Shchelochkov, Oleg A.
Dickinson, Klara
Scharschmidt, Bruce F.
Lee, Brendan
Marino, Miguel
Le Mons, Cynthia
author_facet Shchelochkov, Oleg A.
Dickinson, Klara
Scharschmidt, Bruce F.
Lee, Brendan
Marino, Miguel
Le Mons, Cynthia
author_sort Shchelochkov, Oleg A.
collection PubMed
description Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patient, caregiver (CG) and physician perspectives on treatments used in urea cycle disorders (UCD). METHODS: A paper and online survey assessed experience with UCD medications, medical foods and dietary supplements. RESULTS: 25 physicians, 52 adult patients and 114 CG responded. In 2009, the most common UCD-specific intervention reported by patients included sodium phenylbutyrate (60%), followed by l-citrulline (46%), amino acid medical foods (15%), l-arginine preparations (18%), and sodium benzoate (8%). Only 36% of patients reported experiencing no hyperammonemic episodes in the last 2 years. The most commonly reported cause of hyperammonemic episodes was infection or other acute illnesses, followed by dietary indiscretion, side effects of medications, and drug non-adherence. Most patients, caregivers and physicians (> 75%) ranked nitrogen-scavenging medications, l-citrulline, l-arginine, and medical foods as “effective” or “very effective.” Non-adherence was common (e.g. 18% of patients admitted to missing sodium phenylbutyrate “at least once a week” and “at least one a day”). Barriers to adherence included taste of medications, frequency of drug administration, number of pills, difficulty swallowing pills, side effects, forgetting to take medications, and high cost. Strategies to mitigate the gastrointestinal side effects of medications included the use of gastric tubes and acid reflux medications. Physicians indicated that 25% and 33% of pediatric and adult patients, respectively, were given less than the recommended dose of sodium phenylbutyrate due to concerns of tolerance, administration, and cost. CONCLUSIONS: Despite positive views of their effectiveness, respondents found medications, medical foods and dietary supplements difficult to take and viewed adherence as inadequate, thus contributing to hyperammonemic episodes.
format Online
Article
Text
id pubmed-4963256
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49632562016-08-04 Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives Shchelochkov, Oleg A. Dickinson, Klara Scharschmidt, Bruce F. Lee, Brendan Marino, Miguel Le Mons, Cynthia Mol Genet Metab Rep Research Paper Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patient, caregiver (CG) and physician perspectives on treatments used in urea cycle disorders (UCD). METHODS: A paper and online survey assessed experience with UCD medications, medical foods and dietary supplements. RESULTS: 25 physicians, 52 adult patients and 114 CG responded. In 2009, the most common UCD-specific intervention reported by patients included sodium phenylbutyrate (60%), followed by l-citrulline (46%), amino acid medical foods (15%), l-arginine preparations (18%), and sodium benzoate (8%). Only 36% of patients reported experiencing no hyperammonemic episodes in the last 2 years. The most commonly reported cause of hyperammonemic episodes was infection or other acute illnesses, followed by dietary indiscretion, side effects of medications, and drug non-adherence. Most patients, caregivers and physicians (> 75%) ranked nitrogen-scavenging medications, l-citrulline, l-arginine, and medical foods as “effective” or “very effective.” Non-adherence was common (e.g. 18% of patients admitted to missing sodium phenylbutyrate “at least once a week” and “at least one a day”). Barriers to adherence included taste of medications, frequency of drug administration, number of pills, difficulty swallowing pills, side effects, forgetting to take medications, and high cost. Strategies to mitigate the gastrointestinal side effects of medications included the use of gastric tubes and acid reflux medications. Physicians indicated that 25% and 33% of pediatric and adult patients, respectively, were given less than the recommended dose of sodium phenylbutyrate due to concerns of tolerance, administration, and cost. CONCLUSIONS: Despite positive views of their effectiveness, respondents found medications, medical foods and dietary supplements difficult to take and viewed adherence as inadequate, thus contributing to hyperammonemic episodes. Elsevier 2016-07-20 /pmc/articles/PMC4963256/ /pubmed/27493880 http://dx.doi.org/10.1016/j.ymgmr.2016.07.003 Text en © 2016 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Shchelochkov, Oleg A.
Dickinson, Klara
Scharschmidt, Bruce F.
Lee, Brendan
Marino, Miguel
Le Mons, Cynthia
Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title_full Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title_fullStr Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title_full_unstemmed Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title_short Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
title_sort barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963256/
https://www.ncbi.nlm.nih.gov/pubmed/27493880
http://dx.doi.org/10.1016/j.ymgmr.2016.07.003
work_keys_str_mv AT shchelochkovolega barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives
AT dickinsonklara barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives
AT scharschmidtbrucef barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives
AT leebrendan barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives
AT marinomiguel barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives
AT lemonscynthia barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives